ClinicalTrials.gg
CompletedNCT02218697Updated Apr 3, 2018Results posted

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

A Phase 3 interventional study of Influsplit™ Tetra (Fluarix™ Tetra) and Pneumovax™ 23 in Influenza, sponsored by GlaxoSmithKline. Completed at 6 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
357
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.

Enrollment
80th of 165
357 · median 324
Started
2014
with 3 others
Phase 3
74 of 187
2 open now
Registered
161st of 187
by date

Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 80th largest by enrollment of the 165 interventional ones that give a count, is one of 4 that started in 2014, is one of 74 in phase 3, and was the 161st registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Influenza, Human by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the immunogenicity and safety when GSK Biologicals' influenza vaccine Influsplit™ Tetra (Fluarix™ Tetra) is co-administered with Merck \& Co. Inc.'s pneumococcal vaccine (Pneumovax™23/Pneumovax) in adults 50 years of age and older at risk for complications from influenza and pneumococcal infections.

03

Conditions studied

  • Influenza

Keywords

  • Immunogenicity
  • Influsplit Tetra (Fluarix Tetra) 2014/2015 season
  • Safety
  • Adults
  • Pneumovax 23/Pneumovax
  • Co-administration
  • Elderly
  • Seasonal influenza
  • Pneumococcal infection
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • A male or female aged 50 years or above at the time of the first vaccination at risk for complications from influenza and/or pneumococcal infections, meeting their respective countries' recommendations for vaccination against influenza and pneumococcal disease.

    • At risk subjects include adults with chronic respiratory, heart, kidney, liver or neurological disease; (HIV) disease on combination antiretroviral therapy (cART) with cluster of differentiation 4 (CD4) T-cell counts greater than 350 cells/mm3; sickle cell disease or coeliac syndrome that may lead to splenic dysfunction (all other asplenics are excluded). The decision to enrol should be based on the investigators clinical judgement.
  • Written obtained from the subject.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs within six months prior to the first vaccine dose. Inhaled, topical and low-dose intra-articular are allowed.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose and 30 days after the last dose of vaccine.
  • Administration of such a vaccine has to be documented in the "Concomitant vaccination" of the electronic Case Report Form (eCRF).
  • Administration of long-acting immune-modifying drugs/treatment within six months prior to the first vaccine dose or expected administration at any time during the study period. These immunosuppressant drugs/treatment/Biologics include:

    • Methotrexate
    • Leflunomide
    • Azathioprine and 6-mercaptopurine
    • Cyclosporin A
    • Cyclophosphamide
    • Tacrolimus, everolimus, sirolimus, temsirolimus
    • Mycophenolate mofetil
    • Antilymfocytaire immunoglobulins
    • Tumor Necrosis Factor (TNF) inhibitors: Adalimumab (Humira®), certolizumab (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®) and infliximab(Remicade®)
    • Monoclonal antibodies and other biologicals: Rituximab (Mabthera®), Abatacept (Orencia®), tocilizumab (RoActemra®), basiliximab (Simulect®), Natalizumab (Tysabri®) cluster of differentiation 3 (CD3), ...
    • Antitumor agents: alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase inhibitors, microtubule inhibitors and other anti-tumor agents
    • Lenalidomide Revlimid®
    • Tasonermin: Beromun®
    • Proleukin® (aldesleukin; Novartis, ...)
    • Tyrosine kinase inhibitor (Glivec®)Omalizumab Xolair®
    • Eculizumab Soliris® The above list is compiled from: [Federal Public Service Belgium: Health, Food Chain Safety and Environment].
    • Any immunosuppressive treatment which in the opinion of the investigator will not allow an adequate immune response. Inhaled, topical and low-dose intra-articular steroids are allowed.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Previous vaccination with a pneumococcal vaccine within the last five years.
  • Previous vaccination with an influenza vaccine within the last six months.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. infected subjects on cART with above 350 cells/mm3 can be enrolled.
  • History of any reaction or likely to be exacerbated by any component of the vaccines.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 38.0°C (100.4°F). The preferred route for recording temperature in this study will be axillary.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever [≥ 38.0°C (100.4°F)] may be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions.
  • Any condition which, in the opinion of the investigator, prevents the subject from participating in the study or would make intramuscular (IM) injection unsafe.
  • Asplenia or dysfunction of the spleen. This excludes homozygous sickle cell disease or coeliac syndrome that may lead to splenic dysfunction.
  • Acute (i.e. a medically significant change from baseline condition in the past 30 days) pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  • History of chronic alcohol consumption and/or drug abuse.
  • History of Guillain-Barré syndrome.
  • A history of anaphylaxis following ANY vaccination.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
357 participants (actual)

Study arms

  • Experimental
    Co-Ad Group

    Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.

    Biological: Influsplit™ Tetra (Fluarix™ Tetra) · Biological: Pneumovax™ 23 · Biological: Placebo (Saline)

  • Experimental
    Control Group

    Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.

    Biological: Influsplit™ Tetra (Fluarix™ Tetra) · Biological: Pneumovax™ 23 · Biological: Placebo (Saline)

Interventions

  • BiologicalInflusplit™ Tetra (Fluarix™ Tetra)

    Intramuscular injection, 1 dose each in Control and Co-Ad groups.

    Also known as: D-QIV, GSK2321138A

  • BiologicalPneumovax™ 23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Intramuscular injection, 1 dose each in Control and Co-Ad groups.

  • BiologicalPlacebo (Saline)

    Intramuscular injection, 1 dose each in Control and Co-Ad groups.

06

What researchers measure

Primary outcomes

  1. Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies Titers Against the 4 Vaccine Strains.

    HI antibody titres were expressed as geometric mean titers (GMTs) and adjusted GMT ratios (Control Group/Co-Ad Group). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), FluA/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).

    Time frame: At Day 28 post Influsplit™ Tetra vaccination

  2. Pneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 6 Pneumococcal Serotypes (1, 3, 4, 7F, 14 and 19A).

    Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) and adjusted GMC ratio (Control Group/Co-Ad Group).

    Time frame: At 28 days after Pneumovax™ 23 vaccination

Secondary outcomes

  1. Number of Subjects Reporting Solicited Local Adverse Events (AEs)

    Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain = significant pain at rest and pain that prevented normal everyday activities. Grade 3 redness and swelling = greater than 50 millimeters (mm) i.e. \> 100mm.

    Time frame: Within 7 days (Days 0 - 6) after each dose and across doses.

  2. Number of Subjects Reporting Solicited General Adverse Events (AEs)

    Solicited general symptoms assessed were fatigue, gastrointestinal symptoms\*, headache, joint pain, muscle aches, shivering, sweating and fever. Any was defined as any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 was defined as symptoms that prevented normal everyday activities. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as temperature greater than (\>)39.0°C. \*Gastrointestinal (GI) symptoms included nausea, vomiting, diarrhoea and/or abdominal pain

    Time frame: Within 7 days (Days 0 - 6) after each dose and across doses.

  3. Duration of Local Adverse Events

    Duration was defined as number of days with any grade of local symptoms.

    Time frame: During the 7-day (Days 0-6) post-vaccination period

  4. Duration of Solicited General AEs.

    Duration was defined as number of days with any grade of general symptoms.

    Time frame: During the 7-day (Days 0-6) post-vaccination period

  5. Number of Subjects Reporting the Occurrence of Medically Attended Adverse Events (MAEs)

    MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s) regardless of intensity grade or relationship to vaccination. Related was defined as MAE assessed by the investigator to be causally related to the study vaccination.

    Time frame: Throughout the study period (Days 0-180)

  6. Number of Subjects Reporting the Occurrence of Potential Immune Mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) were defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any was defined as any occurrence of pIMD(s) regardless of intensity grade or relationship to vaccination. Related was defined as pIMD assessed by the investigator to be causally related to the study vaccination.

    Time frame: During the entire study period (Days 0-180)

  7. Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).

    An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.

    Time frame: Within the 28-day (Days 0-27) post-vaccination period

  8. Number of Subjects Reporting Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.

    Time frame: Throughout the study period (Days 0-180)

  9. Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies in Subjects by Calculating Serum Antihaemagglutination (HA) Antibody Titers Against the 4 Influenza Vaccine Strains

    HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).

    Time frame: At Day 0 and Day 28

  10. Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.

    A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).

    Time frame: At Day 0 and Day 28

  11. Number of Seroconverted Subjects for Anti-Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.

    A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).

    Time frame: At Day 28

  12. Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Four Vaccine Influenza Strains.

    MGI was defined as the fold increase in serum haemagglutination inhibition (HI) GMTs post-vaccination compared to pre-vaccination (Day 0). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).

    Time frame: At Day 28

  13. Number of Subjects With Anti-pneumococcal Antibody Concentrations for the Following Serotypes: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F

    The pneumococcal antigen testing was performed, as determined by ELISA cut-offs of ≥0.05 µg/mL and a seroprotection cut-off of ≥ 0.2 µg/ml. PRE = Pre-vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.

    Time frame: At Days 0 (Co-Ad group only), 28 (both groups), and 56 (Control group only)

  14. Pneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 12 Pneumococcal Serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F)

    Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) PRE = Pre -vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.

    Time frame: At Days 0 (Co-Ad group only), 28 (both groups), and 56 (Control group only)

  15. Number of Subjects Whose N Antibody Titers Were at Least 2 or 4-fold Higher Than Their Pre-vaccination Titer by Anti-pneumococcal Serotype Subjects.

    Fold antibody concentration increases post-vaccination/pre-vaccination ≥ 2 and ≥ 4. The anti-pneumococcal serotypes assessed were 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

    Time frame: At 28 days post-vaccination with Pneumovax™ 23

07

Results

Posted Mar 9, 2017

Participant flow

In the Control Group, 2 subjects withdrew at Day 0. In the Co-Ad Group, 4 subjects withdrew at Day 0, 1 subject withdrew at Day 28 and 1 subject withdrew at Day 56.

Participant flow — Overall Study
MilestoneControl GroupCo-Ad Group
Started179177
Completed177171
Not completed26
Withdrew: Adverse event02
Withdrew: Unwilling to be vaccinated in left arm01
Withdrew: Withdrawal by subject23

Outcome measures

PrimaryHumoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies Titers Against the 4 Vaccine Strains.

HI antibody titres were expressed as geometric mean titers (GMTs) and adjusted GMT ratios (Control Group/Co-Ad Group). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), FluA/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).

Time frame:
At Day 28 post Influsplit™ Tetra vaccination
Reported as:
Geometric mean · Titers
Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies Titers Against the 4 Vaccine Strains.
TitersControl GroupCo-Ad Group
H1N1253.2 (205.3 to 312.1)235.5 (195.0 to 284.5)
H3N273.6 (62.1 to 87.1)78.6 (65.2 to 94.7)
Victoria178.7 (154.9 to 206.2)157.9 (136.4 to 182.9)
Yamagata346.5 (302.3 to 397.1)353.8 (310.5 to 403.2)
Statistical analysis
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmt ratio: 1.13 · 95% CI 0.88 to 1.46The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmt ratio: 0.97 · 95% CI 0.78 to 1.21The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmt ratio: 1.17 · 95% CI 0.98 to 1.40The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmt ratio: 0.99 · 95% CI 0.84 to 1.16The GMTs were used to calculate the Adjusted GMTs, which in turn were used to calculate the Adjusted GMT ratio with 95% confidence interval.
PrimaryPneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 6 Pneumococcal Serotypes (1, 3, 4, 7F, 14 and 19A).

Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) and adjusted GMC ratio (Control Group/Co-Ad Group).

Time frame:
At 28 days after Pneumovax™ 23 vaccination
Reported as:
Geometric mean · ug per ml
Pneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 6 Pneumococcal Serotypes (1, 3, 4, 7F, 14 and 19A).
ug per mlControl GroupCo-Ad Group
Polysaccharide 01 IgG5.5 (4.3 to 7.0)4.9 (3.9 to 6.2)
Polysaccharide 03 IgG1.7 (1.4 to 2.1)1.7 (1.4 to 2.0)
Polysaccharide 04 IgG2.3 (1.8 to 2.9)1.7 (1.4 to 2.2)
Polysaccharide 7F IgG9.0 (6.9 to 11.8)8.1 (6.2 to 10.6)
Polysaccharide 14 IgG20.2 (16.0 to 25.6)14.1 (11.3 to 17.6)
Polysaccharide 19A IgG9.2 (7.1 to 11.9)7.7 (6.1 to 9.8)
Statistical analysis
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmc ratio: 1.14 · 95% CI 0.86 to 1.50The GMCs were used to calculate the Adjusted GMCs, which in turn were used to calculate the Adjusted GMC ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmc ratio: 1.18 · 95% CI 0.96 to 1.45The GMCs were used to calculate the Adjusted GMCs, which in turn were used to calculate the Adjusted GMC ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmc ratio: 1.26 · 95% CI 0.98 to 1.62The GMCs were used to calculate the Adjusted GMCs, which in turn were used to calculate the Adjusted GMC ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmc ratio: 1.24 · 95% CI 0.95 to 1.63The GMCs were used to calculate the Adjusted GMCs, which in turn were used to calculate the Adjusted GMC ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmc ratio: 1.20 · 95% CI 0.91 to 1.57The GMCs were used to calculate the Adjusted GMCs, which in turn were used to calculate the Adjusted GMC ratio with 95% confidence interval.
  • Control Group vs Co-Ad Group · ANCOVA · Adjusted gmc ratio: 1.34 · 95% CI 1.05 to 1.70The GMCs were used to calculate the Adjusted GMCs, which in turn were used to calculate the Adjusted GMC ratio with 95% confidence interval.
SecondaryNumber of Subjects Reporting Solicited Local Adverse Events (AEs)

Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain = significant pain at rest and pain that prevented normal everyday activities. Grade 3 redness and swelling = greater than 50 millimeters (mm) i.e. \> 100mm.

Time frame:
Within 7 days (Days 0 - 6) after each dose and across doses.
Reported as:
Number · Subjects
Number of Subjects Reporting Solicited Local Adverse Events (AEs)
SubjectsControl GroupCo-Ad Group
Any Pain, Dose 1 (Influsplit™ Tetra)2858
Grade 3 Pain,Dose 1(Influsplit™ Tetra)02
Any Pain, Dose 1 (Placebo)10—
Grade 3 Pain, Dose 1 (Placebo)0—
Any Pain, Dose 1 (Pneumovax™ 23)—76
Grade 3 Pain, Dose 1 (Pneumovax™ 23)—6
Any Redness, Dose 1 (Influsplit™ Tetra)32
Grade3 Redness,Dose 1(Influsplit™ Tetra)00
Any Redness, Dose 1 (Placebo)3—
Grade 3 Redness, Dose 1 (Placebo)0—
Any Redness, Dose 1 (Pneumovax™ 23)—8
Grade 3 Redness, Dose 1 (Pneumovax™ 23)—0
Any Swelling, Dose1 (Influsplit™ Tetra)13
Grade3 Swelling,Dose1(Influsplit™ Tetra)00
Any Swelling, Dose 1 (Placebo)1—
Grade 3 Swelling, Dose 1 (Placebo)0—
Any Swelling, Dose 1 (Pneumovax™ 23)—7
Grade 3 Swelling,Dose 1 (Pneumovax™ 23)—0
Any Pain, Dose 2 (Placebo)—8
Grade 3 Pain, Dose 2 (Placebo)—0
Any Pain, Dose 2 (Pneumovax™ 23)63—
Grade 3 Pain, Dose 2 (Pneumovax™ 23)8—
Any Redness, Dose 2 (Placebo)—1
Grade 3 Redness, Dose 2 (Placebo)—0
Any Redness, Dose 2 (Pneumovax™ 23)8—
Grade 3 Redness, Dose 2 (Pneumovax™ 23)1—
Any Swelling, Dose 2 (Placebo)—0
Grade 3 Swelling, Dose 2 (Placebo)—0
Any Swelling, Dose 2 (Pneumovax™ 23)5—
Grade 3 Swelling, Dose 2 (Pneumovax™ 23)1—
Any Pain, Across Doses (Influsplit™ Tetra)2858
Grade 3 Pain, Across Doses (Influsplit™Tetra)02
Any Pain, Across Doses (Placebo)108
Grade 3 Pain, Across Doses (Placebo)00
Any Pain, Across Doses (Pneumovax™ 23)6376
Grade 3 Pain, Across Doses (Pneumovax™ 23)86
Any Redness, Across Doses (Influsplit™Tetra)32
Grade 3 Redness, Across Doses (Influsplit™ Tetra)00
Any Redness, Across Doses (Placebo)31
Grade 3 Redness, Across Doses (Placebo)00
Any Redness, Across Doses (Pneumovax™ 23)88
Grade 3 Redness, Across Doses (Pneumovax™23)10
Any Swelling, Across Doses (Influsplit™Tetra)13
Grade 3 Swelling, Across Doses (Influsplit™Tetra)00
Any Swelling, Across Doses (Placebo)10
Grade 3 Swelling, Across Doses (Placebo)00
Any Swelling, Across Doses (Pneumovax™23)57
Grade 3 Swelling, Across Doses (Pneumovax™23)10
SecondaryNumber of Subjects Reporting Solicited General Adverse Events (AEs)

Solicited general symptoms assessed were fatigue, gastrointestinal symptoms\*, headache, joint pain, muscle aches, shivering, sweating and fever. Any was defined as any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 was defined as symptoms that prevented normal everyday activities. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as temperature greater than (\>)39.0°C. \*Gastrointestinal (GI) symptoms included nausea, vomiting, diarrhoea and/or abdominal pain

Time frame:
Within 7 days (Days 0 - 6) after each dose and across doses.
Reported as:
Number · Subjects
Number of Subjects Reporting Solicited General Adverse Events (AEs)
SubjectsControl GroupCo-Ad Group
Any Fatigue, Dose 13039
Grade 3 Fatigue, Dose 112
Related Fatigue, Dose 12333
Any GI symptoms, Dose 11612
Grade 3 GI symptoms, Dose 111
Related GI symptoms, Dose 195
Any Headache, Dose 12120
Grade 3 Headache, Dose 102
Related Headache, Dose 11317
Any Joint pain, Dose 11116
Grade 3 Joint pain, Dose 100
Related Joint pain, Dose 1614
Any Muscle aches, Dose 11520
Grade 3 Muscle aches, Dose 101
Related Muscle aches, Dose 11219
Any Shivering, Dose 1610
Grade 3 Shivering, Dose 101
Related Shivering, Dose 158
Any Sweating, Dose 11116
Grade 3 Sweating, Dose 101
Related Sweating, Dose 1910
Any Fever, Dose 102
Grade 3 Fever, Dose 101
Related Fever, Dose 102
Any Fatigue, Dose 22512
Grade 3 Fatigue, Dose 210
Related Fatigue, Dose 2226
Any GI symptoms, Dose 2117
Grade 3 GI symptoms, Dose 201
Related GI symptoms, Dose 292
Any Headache, Dose 21810
Grade 3 Headache, Dose 210
Related Headache, Dose 2143
Any Joint pain, Dose 21711
Grade 3 Joint pain, Dose 210
Related Joint pain, Dose 2127
Any Muscle aches, Dose 22112
Grade 3 Muscle aches, Dose 240
Related Muscle aches, Dose 2196
Any Shivering, Dose 285
Grade 3 Shivering, Dose 210
Related Shivering, Dose 253
Any Sweating, Dose 2108
Grade 3 Sweating, Dose 210
Related Sweating, Dose 255
Any Fever, Dose 210
Grade 3 Fever, Dose 200
Related Fever, Dose 210
Any Fatigue, Across Doses4343
Grade 3 Fatigue, Across Doses22
Related Fatigue, Across Doses3437
Any GI symptoms, Across Doses2317
Grade 3 GI symptoms, Across Doses12
Related GI symptoms, Across Doses157
Any Headache, Across Doses3027
Grade 3 Headache, Across Doses12
Related Headache, Across Doses2220
Any Joint pain, Across Doses2523
Grade 3 Joint pain, Across Doses10
Related Joint pain, Across Doses1620
Any Muscle aches, Across Doses3228
Grade 3 Muscle aches, Across Doses41
Related Muscle aches, Across Doses2824
Any Shivering, Across Doses1314
Grade 3 Shivering, Across Doses11
Related Shivering, Across Doses910
Any Sweating, Across Doses1619
Grade 3 Sweating, Across Doses11
Related Sweating, Across Doses1114
Any Fever, Across Doses12
Grade 3 Fever, Across Doses01
Related Fever, Across Doses12
SecondaryDuration of Local Adverse Events

Duration was defined as number of days with any grade of local symptoms.

Time frame:
During the 7-day (Days 0-6) post-vaccination period
Reported as:
Median · Days
Duration of Local Adverse Events
DaysControl GroupCo-Ad Group
Pain, Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Pain, Dose 22.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Redness, Dose 14.0 (3.0 to 4.0)2.0 (2.0 to 3.0)
Redness, Dose 22.0 (1.0 to 2.5)1.0 (1.0 to 1.0)
Swelling, Dose 14.5 (4.0 to 5.0)2.0 (2.0 to 4.0)
Swelling, Dose 23.0 (1.0 to 5.0)—
SecondaryDuration of Solicited General AEs.

Duration was defined as number of days with any grade of general symptoms.

Time frame:
During the 7-day (Days 0-6) post-vaccination period
Reported as:
Median · Days
Duration of Solicited General AEs.
DaysControl GroupCo-Ad Group
Fatigue, Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Fatigue, Dose 23.0 (2.0 to 4.0)3.5 (1.5 to 6.5)
Gastrointestinal symptoms, Dose 12.0 (1.0 to 4.0)2.0 (1.0 to 2.0)
Gastrointestinal symptoms, Dose 23.0 (2.0 to 3.0)3.0 (2.0 to 6.0)
Headache, Dose 11.0 (1.0 to 2.0)1.5 (1.0 to 2.5)
Headache, Dose 22.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Joint pain, Dose 12.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Joint pain, Dose 22.0 (2.0 to 3.0)2.0 (1.0 to 7.0)
Muscle aches, Dose 12.0 (1.0 to 3.0)3.0 (1.5 to 4.5)
Muscle aches, Dose 22.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
Sweating, Dose 12.0 (1.0 to 6.0)2.0 (1.0 to 3.5)
Sweating, Dose 22.0 (1.0 to 5.0)2.0 (1.5 to 2.0)
Shivering, Dose 12.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Shivering, Dose 21.0 (1.0 to 2.0)3.0 (1.0 to 3.0)
Fever, Dose 1—1.0 (1.0 to 1.0)
Fever, Dose 21.0 (1.0 to 1.0)—
SecondaryNumber of Subjects Reporting the Occurrence of Medically Attended Adverse Events (MAEs)

MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s) regardless of intensity grade or relationship to vaccination. Related was defined as MAE assessed by the investigator to be causally related to the study vaccination.

Time frame:
Throughout the study period (Days 0-180)
Reported as:
Number · Subjects
Number of Subjects Reporting the Occurrence of Medically Attended Adverse Events (MAEs)
SubjectsControl GroupCo-Ad Group
Any MAE(s)3743
Related MAE(s)22
SecondaryNumber of Subjects Reporting the Occurrence of Potential Immune Mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) were defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any was defined as any occurrence of pIMD(s) regardless of intensity grade or relationship to vaccination. Related was defined as pIMD assessed by the investigator to be causally related to the study vaccination.

Time frame:
During the entire study period (Days 0-180)
Reported as:
Number · Subjects
Number of Subjects Reporting the Occurrence of Potential Immune Mediated Diseases (pIMDs)
SubjectsControl GroupCo-Ad Group
Any pIMD(s)01
Related pIMD(s)00
SecondaryNumber of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).

An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.

Time frame:
Within the 28-day (Days 0-27) post-vaccination period
Reported as:
Number · Subjects
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).
SubjectsControl GroupCo-Ad Group
Any Unsolicited AEs3542
Grade 3 Unsolicited AEs58
Related Unsolicited AEs55
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.

Time frame:
Throughout the study period (Days 0-180)
Reported as:
Number · Subjects
Number of Subjects Reporting Serious Adverse Events (SAEs)
SubjectsControl GroupCo-Ad Group
Any SAE(s)117
Related SAE(s)00
Fatal SAE(s)01
Related Fatal SAE(s)00
SecondaryHumoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies in Subjects by Calculating Serum Antihaemagglutination (HA) Antibody Titers Against the 4 Influenza Vaccine Strains

HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).

Time frame:
At Day 0 and Day 28
Reported as:
Geometric mean · Titers
Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies in Subjects by Calculating Serum Antihaemagglutination (HA) Antibody Titers Against the 4 Influenza Vaccine Strains
TitersControl GroupCo-Ad Group
H1N1, Day 032.4 (26.3 to 39.9)253.2 (205.3 to 312.1)
H1N1, Day 2834.0 (27.8 to 41.7)235.5 (195.0 to 284.5)
H3N2, Day 020.8 (17.5 to 24.9)21.8 (18.2 to 26.2)
H3N2, Day 2873.6 (62.1 to 87.1)78.6 (65.2 to 94.7)
Victoria, Day 048.7 (41.6 to 57.1)51.5 (43.9 to 60.3)
Victoria, Day 28178.7 (154.9 to 206.2)157.9 (136.4 to 182.9)
Yamagata, Day 0120.7 (104.3 to 139.8)119.9 (103.0 to 139.5)
Yamagata, Day 28346.5 (302.3 to 397.1)353.8 (310.5 to 403.2)
SecondaryNumber of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.

A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).

Time frame:
At Day 0 and Day 28
Reported as:
Number · Subjects
Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.
SubjectsControl GroupCo-Ad Group
H1N1, Day 08377
H1N1, Day 28160157
H3N2, Day 05750
H3N2, Day 28131128
Victoria, Day 0106113
Victoria, Day 28167154
Yamagata, Day 0159146
Yamagata, Day 28169162
SecondaryNumber of Seroconverted Subjects for Anti-Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).

Time frame:
At Day 28
Reported as:
Number · Subjects
Number of Seroconverted Subjects for Anti-Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.
SubjectsControl GroupCo-Ad Group
H1N1110101
H3N26261
Victoria7355
Yamagata6054
SecondaryMean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Four Vaccine Influenza Strains.

MGI was defined as the fold increase in serum haemagglutination inhibition (HI) GMTs post-vaccination compared to pre-vaccination (Day 0). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).

Time frame:
At Day 28
Reported as:
Geometric mean · Fold increase
Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Four Vaccine Influenza Strains.
Fold increaseControl GroupCo-Ad Group
H1N17.7 (6.1 to 9.7)6.9 (5.5 to 8.6)
H3N23.5 (3.0 to 4.2)3.6 (3.0 to 4.4)
Victoria3.6 (3.1 to 4.3)3.1 (2.6 to 3.6)
Yamagata2.8 (2.5 to 3.3)3.0 (2.5 to 3.4)
SecondaryNumber of Subjects With Anti-pneumococcal Antibody Concentrations for the Following Serotypes: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F

The pneumococcal antigen testing was performed, as determined by ELISA cut-offs of ≥0.05 µg/mL and a seroprotection cut-off of ≥ 0.2 µg/ml. PRE = Pre-vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.

Time frame:
At Days 0 (Co-Ad group only), 28 (both groups), and 56 (Control group only)
Reported as:
Number · Subjects
Number of Subjects With Anti-pneumococcal Antibody Concentrations for the Following Serotypes: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
SubjectsControl GroupCo-Ad Group
Polysaccharide 01 Ab.IgG (≥ 0.05 µg/ml) (PRE)162152
Polysaccharide 01 Ab.IgG (≥ 0.05 µg/ml) (POST)169162
Polysaccharide 01 Ab.IgG (≥ 0.2 µg/ml) (PRE)112118
Polysaccharide 01 Ab.IgG (≥ 0.2 µg/ml) (POST)167159
Polysaccharide 03 Ab.IgG (≥ 0.05 µg/ml) (PRE)158149
Polysaccharide 03 Ab.IgG (≥ 0.05 µg/ml) (POST)167161
Polysaccharide 03 Ab.IgG (≥ 0.2 µg/ml) (PRE)114121
Polysaccharide 03 Ab.IgG (≥ 0.2 µg/ml) (POST)158153
Polysaccharide 04 Ab.IgG (≥ 0.05 µg/ml) (PRE)138129
Polysaccharide 04 Ab.IgG (≥ 0.05 µg/ml) (POST)167158
Polysaccharide 04 Ab.IgG (≥ 0.2 µg/ml) (PRE)7782
Polysaccharide 04 Ab.IgG (≥ 0.2 µg/ml) (POST)158149
Polysaccharide 05 Ab.IgG5 (≥ 0.05 µg/ml) (PRE)165159
Polysaccharide 05 Ab.IgG5 (≥ 0.05 µg/ml) (POST)169162
Polysaccharide 05 Ab.IgG5 (≥ 0.2 µg/ml) (PRE)130115
Polysaccharide 05 Ab.IgG5 (≥ 0.2 µg/ml) (POST)163155
Polysaccharide 6B Ab.IgG (≥ 0.05 µg/ml) (PRE)158149
Polysaccharide 6B Ab.IgG (≥ 0.05 µg/ml) (POST)164160
Polysaccharide 6B Ab.IgG (≥ 0.2 µg/ml) (PRE)106110
Polysaccharide 6B Ab.IgG (≥ 0.2 µg/ml) (POST)157147
Polysaccharide 7F Ab.IgG (≥ 0.05 µg/ml) (PRE)159154
Polysaccharide 7F Ab.IgG (≥ 0.05 µg/ml) (POST)169162
Polysaccharide 7F Ab.IgG (≥ 0.2 µg/ml) (PRE)127130
Polysaccharide 7F Ab.IgG (≥ 0.2 µg/ml) (POST)165161
Polysaccharide 9V Ab.IgG (≥ 0.05 µg/ml) (PRE)165150
Polysaccharide 9V Ab.IgG (≥ 0.05 µg/ml) (POST)168160
Polysaccharide 9V Ab.IgG (≥ 0.2 µg/ml) (PRE)123117
Polysaccharide 9V Ab.IgG (≥ 0.2 µg/ml) (POST)166157
Polysaccharide 14 Ab.IgG (≥ 0.05 µg/ml) (PRE)170163
Polysaccharide 14 Ab.IgG (≥ 0.05 µg/ml) (POST)169162
Polysaccharide 14 Ab.IgG (≥ 0.2 µg/ml) (PRE)168160
Polysaccharide 14 Ab.IgG (≥ 0.2 µg/ml) (POST)168162
Polysaccharide 18C Ab.IgG (≥ 0.05 µg/ml) (PRE)166161
Polysaccharide 18C Ab.IgG (≥ 0.05 µg/ml) (POST)169162
Polysaccharide 18C Ab.IgG (≥ 0.2 µg/ml) (PRE)154148
Polysaccharide 18C Ab.IgG (≥ 0.2 µg/ml) (POST)168159
Polysaccharide 19A Ab.IgG (≥ 0.05 µg/ml) (PRE)168160
Polysaccharide 19A Ab.IgG (≥ 0.05 µg/ml) (POST)169161
Polysaccharide 19A Ab.IgG (≥ 0.2 µg/ml) (PRE)146148
Polysaccharide 19A Ab.IgG (≥ 0.2 µg/ml) (POST)165158
Polysaccharide 19F Ab.IgG (≥ 0.05 µg/ml) (PRE)169160
Polysaccharide 19F Ab.IgG (≥ 0.05 µg/ml) (POST)169162
Polysaccharide 19F Ab.IgG (≥ 0.2 µg/ml) (PRE)151152
Polysaccharide 19F Ab.IgG (≥ 0.2 µg/ml) (POST)169161
Polysaccharide 23F Ab.IgG (≥ 0.05 µg/ml) (PRE)151151
Polysaccharide 23F Ab.IgG (≥ 0.05 µg/ml) (POST)165159
Polysaccharide 23F Ab.IgG (≥ 0.2 µg/ml) (PRE)112125
Polysaccharide 23F Ab.IgG (≥ 0.2 µg/ml) (POST)155147
SecondaryPneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 12 Pneumococcal Serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F)

Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) PRE = Pre -vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.

Time frame:
At Days 0 (Co-Ad group only), 28 (both groups), and 56 (Control group only)
Reported as:
Geometric mean · Titers
Pneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 12 Pneumococcal Serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F)
TitersControl GroupCo-Ad Group
Polysaccharide 01 Ab.IgG (PRE)0.4 (0.3 to 0.5)0.4 (0.3 to 0.5)
Polysaccharide 01 Ab.IgG (POST)5.5 (4.3 to 7.0)4.9 (3.9 to 6.2)
Polysaccharide 03 Ab.IgG (PRE)0.4 (0.3 to 0.5)0.5 (0.4 to 0.6)
Polysaccharide 03 Ab.IgG (POST)1.7 (1.4 to 2.1)1.7 (1.4 to 2.0)
Polysaccharide 04 Ab.IgG (PRE)0.2 (0.2 to 0.3)0.2 (0.2 to 0.2)
Polysaccharide 04 Ab.IgG (POST)2.3 (1.8 to 2.9)1.7 (1.4 to 2.2)
Polysaccharide 05 Ab.IgG5 (PRE)0.6 (0.5 to 0.7)0.5 (0.4 to 0.6)
Polysaccharide 05 Ab.IgG5 (POST)7.8 (5.9 to 10.4)5.7 (4.3 to 7.5)
Polysaccharide 6B Ab.IgG (PRE)0.4 (0.3 to 0.6)0.4 (0.3 to 0.5)
Polysaccharide 6B Ab.IgG (POST)3.9 (2.9 to 5.1)3.1 (2.3 to 4.1)
Polysaccharide 7F Ab.IgG (PRE)0.6 (0.5 to 0.8)0.7 (0.6 to 0.9)
Polysaccharide 7F Ab.IgG (POST)9.0 (6.9 to 11.8)8.1 (6.2 to 10.6)
Polysaccharide 9V Ab.IgG (PRE)0.5 (0.4 to 0.7)0.5 (0.4 to 0.6)
Polysaccharide 9V Ab.IgG (POST)5.9 (4.8 to 7.4)4.4 (3.6 to 5.5)
Polysaccharide 14 Ab.IgG (PRE)3.7 (3.1 to 4.6)2.9 (2.4 to 3.5)
Polysaccharide 14 Ab.IgG (POST)20.2 (16.0 to 25.6)14.1 (11.3 to 17.6)
Polysaccharide 18C Ab.IgG (PRE)1.4 (1.1 to 1.7)1.2 (1.0 to 1.5)
Polysaccharide 18C Ab.IgG (POST)13.5 (10.7 to 16.8)11.1 (9.0 to 13.6)
Polysaccharide 19A Ab.IgG (PRE)1.3 (1.0 to 1.6)1.5 (1.2 to 1.9)
Polysaccharide 19A Ab.IgG (POST)9.2 (7.1 to 11.9)7.7 (6.1 to 9.8)
Polysaccharide 19F Ab.IgG (PRE)1.3 (1.1 to 1.7)1.4 (1.2 to 1.8)
Polysaccharide 19F Ab.IgG (POST)11.9 (9.3 to 15.2)10.6 (8.4 to 13.6)
Polysaccharide 23F Ab.IgG (PRE)0.4 (0.3 to 0.6)0.5 (0.4 to 0.7)
Polysaccharide 23F Ab.IgG (POST)3.1 (2.3 to 4.1)2.9 (2.2 to 3.8)
SecondaryNumber of Subjects Whose N Antibody Titers Were at Least 2 or 4-fold Higher Than Their Pre-vaccination Titer by Anti-pneumococcal Serotype Subjects.

Fold antibody concentration increases post-vaccination/pre-vaccination ≥ 2 and ≥ 4. The anti-pneumococcal serotypes assessed were 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.

Time frame:
At 28 days post-vaccination with Pneumovax™ 23
Reported as:
Number · Subjects
Number of Subjects Whose N Antibody Titers Were at Least 2 or 4-fold Higher Than Their Pre-vaccination Titer by Anti-pneumococcal Serotype Subjects.
SubjectsControl GroupCo-Ad Group
Polysaccharide 01 Ab.IgG (≥ 2)149144
Polysaccharide 01 Ab.IgG (≥ 4)134126
Polysaccharide 03 Ab.IgG (≥ 2)12197
Polysaccharide 03 Ab.IgG (≥ 4)8065
Polysaccharide 04 Ab.IgG (≥ 2)149137
Polysaccharide 04 Ab.IgG (≥ 4)127112
Polysaccharide 05 Ab.IgG5 (≥ 2)156138
Polysaccharide 05 Ab.IgG5 (≥ 4)127114
Polysaccharide 14 Ab.IgG (≥ 2)123102
Polysaccharide 14 Ab.IgG (≥ 4)9082
Polysaccharide 18C Ab.IgG (≥ 2)149133
Polysaccharide 18C Ab.IgG (≥ 4)123116
Polysaccharide 19A Ab.IgG (≥ 2)133123
Polysaccharide 19A Ab.IgG (≥ 4)11187
Polysaccharide 19F Ab.IgG (≥ 2)146141
Polysaccharide 19F Ab.IgG (≥ 4)111109
Polysaccharide 23F Ab.IgG (≥ 2)133122
Polysaccharide 23F Ab.IgG (≥ 4)10894
Polysaccharide 6B Ab.IgG (≥ 2)141127
Polysaccharide 6B Ab.IgG (≥ 4)113109
Polysaccharide 7F Ab.IgG (≥ 2)155144
Polysaccharide 7F Ab.IgG (≥ 4)138119
Polysaccharide 9V Ab.IgG (≥ 2)146140
Polysaccharide 9V Ab.IgG (≥ 4)131121

Adverse events

Collected over Serious Adverse Events: During the entire study period (Day 0 to 180); Solicited local and general symptoms: During the 7-day (Days 0-6) post-vaccination period; Unsolicited adverse events: During the 28-day (Days 0-27) post-vaccination period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Group—11/179 (6.1%)117/179 (65.4%)
Co-Ad Group—7/177 (4%)127/177 (71.8%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventControl GroupCo-Ad Group
Coronary artery stenosisCardiac disorders2/1790/177
Angina pectorisCardiac disorders0/1791/177
Cardiac failureCardiac disorders0/1791/177
Cardio-respiratory arrestCardiac disorders0/1791/177
Intestinal malrotationCongenital, familial and genetic disorders0/1791/177
Intestinal ischaemiaGastrointestinal disorders0/1791/177
ErysipelasInfections and infestations0/1791/177
Wrist fractureInjury, poisoning and procedural complications0/1791/177
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/1791/177
OsteoarthritisMusculoskeletal and connective tissue disorders0/1791/177
Most frequent other events
Most frequent other events
EventControl GroupCo-Ad Group
PainGeneral disorders76/17992/177
FatigueGeneral disorders43/17943/177
MyalgiaMusculoskeletal and connective tissue disorders32/17928/177
HeadacheNervous system disorders31/17927/177
ArthralgiaMusculoskeletal and connective tissue disorders25/17925/177
Gastrointestinal disorderGastrointestinal disorders23/17917/177
HyperhidrosisSkin and subcutaneous tissue disorders16/17919/177
ChillsGeneral disorders13/17914/177
ErythemaSkin and subcutaneous tissue disorders13/17910/177
SwellingGeneral disorders6/1799/177

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Control GroupCo-Ad GroupTotal
Mean68.4 ± 9.468.1 ± 9.068.3 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Control GroupCo-Ad GroupTotal
Female7776153
Male102101203
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Control GroupCo-Ad GroupTotal
African Heritage / African American123
White - Arabic / North African Heritage314
White - Caucasian / European Heritage175172347
Mixed Origin022
08

Study locations

6 sites
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Laval, 53000, France
  • GSK Investigational Site
    Nantes cedex 2, 44277, France
  • GSK Investigational Site
    Saint Cyr sur Loire, 37540, France
  • GSK Investigational Site
    Tours, 37100, France
09

References and documents

Publications

  • Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults >/=50years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine. 2017 Nov 1;35(46):6321-6328. doi: 10.1016/j.vaccine.2017.09.012. Epub 2017 Oct 5. PubMed 28987445 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Jan 2015, 3 months.

Results were first posted in Mar 2017, 2 years 1 month after primary completion. A results delay was requested in Jan 2016.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2014
First posted
Aug 18, 2014
StartActual
Oct 1, 2014
Primary completionActual
Jan 14, 2015
CompletionActual
May 4, 2015
Results delay requested
Jan 14, 2016
Results first posted
Mar 9, 2017
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02218697
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 18, 2014
Start date
Oct 1, 2014
Primary completion
Jan 14, 2015
Completion
May 4, 2015
Results posted
Mar 9, 2017
Last update
Apr 3, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion